NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,375,623 | -21.3% | 556,695 | 0.0% | 1.36% | -10.5% |
| Q2 2023 | $5,561,383 | +10.5% | 556,695 | -1.8% | 1.52% | +0.8% |
| Q1 2023 | $5,032,252 | -19.1% | 566,695 | 0.0% | 1.51% | -13.9% |
| Q4 2022 | $6,222,311 | -15.7% | 566,695 | 0.0% | 1.75% | -11.8% |
| Q3 2022 | $7,384,000 | +2.8% | 566,695 | 0.0% | 1.99% | +1.5% |
| Q2 2022 | $7,180,000 | -5.7% | 566,695 | +4.3% | 1.96% | -1.3% |
| Q1 2022 | $7,612,000 | -14.2% | 543,344 | +77.4% | 1.98% | -11.1% |
| Q4 2021 | $8,868,000 | -3.4% | 306,320 | 0.0% | 2.23% | -8.4% |
| Q3 2021 | $9,177,000 | +12.9% | 306,320 | 0.0% | 2.44% | +43.2% |
| Q2 2021 | $8,127,000 | -14.7% | 306,320 | 0.0% | 1.70% | -24.7% |
| Q1 2021 | $9,523,000 | – | 306,320 | – | 2.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |